Stock listing

Perspective Therapeutics, Inc.

Selected listing: A40EDR · LSX · EUR · DE

Perspective Therapeutics, Inc. (LS Exchange: A40EDR), Health Technology. Latest release Sep 14, 2026: Perspective Therapeutics Announces Clinical…

A40EDR:LSXEURDEUpdated October 3, 2026

Ticker: LS Exchange: A40EDR
Asset type: Stock
Sector: Health Technology
Industry: Medical Specialties
Exchange: LS Exchange
Currency: EUR

About Perspective Therapeutics, Inc.

The company focuses on developing innovative therapeutic solutions. Its strategic initiatives aim to address unmet medical needs and improve patient outcomes.

Latest news from Perspective Therapeutics, Inc.

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

September 14, 2026

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

July 31, 2026

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

July 28, 2026

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

June 3, 2026

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

May 18, 2026

All Perspective Therapeutics, Inc. news →

Research Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. company profile

View the public company page for Perspective Therapeutics, Inc. on 6ix.

Perspective Therapeutics, Inc. news

Read company news and market updates connected to Perspective Therapeutics, Inc..

Perspective Therapeutics, Inc. investor events

Find investor webinars, events, and replay context for Perspective Therapeutics, Inc..